In Vivo Podcast with David Wild
February 12, 2026
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.... full article
Business of Biotech Podcast: BoB @ JPM: Marc Salzberg, M.D., Airway Therapeutics
January 19, 2026
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics... full article
Scrip Asks… What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking
January 9, 2026
"Marc Salzberg, CEO and chief medical officer of Airway Therapeutics, positioned it even more boldly: “Looking into 2026, capital allocation and dealmaking will concentrate on rare diseases, reflecting a strategic shift across pharmaceutical companies and investors. Competitive high-incidence indications focusing on common targets will be gradually replaced by less crowded rare diseases. Advances in study designs, genomics and regulatory incentives reduce development risks while improving the probability of clinical and commercial success. Rapid market penetration coupled with attractive pricing represent additional incentives. M&A activity, partnerships and venture funding are expected to disproportionately favor orphan indications.”"... full article
Daniele De Luca, MD, discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
November 21, 2025
A phase 1b study of zelpultide alfa demonstrated a favorable safety profile and encouraging early reductions in BPD and ventilation duration, supporting advancement to a pivotal international Phase 2b/3 program.... full article
Empowered Patient Podcast: First Treatment for Severe Respiratory Condition in Premature Babies with Dr. Marc Salzberg Airway Therapeutics
October 20, 2025
Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment.... full article
NPR’s BioTech Nation: New treatment being tested for pre-term babies… Dr. Marc Salzberg, CEO and Chief Medical Officer, Airway Therapeutics
October 2, 2025
Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies.... full article
The Bio Report: Scratching the Surface with a Novel Approach to Treating an Orphan Lung Disease
October 1, 2025
We spoke to Marc Salzberg, CEO of Airway Therapeutics, about the company’s experimental therapy zelpultide alfa, why it’s a pipeline-in-a-product, and its development path forward.... full article
BioSpace with Tristan Manalac, 5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development
August 20, 2025
The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can be a goldmine for smaller companies... full article
Informa’s BioXconomy with Millie Hoe
August 15, 2025
The company will trial its compound zelpultide alfa in over 300 pre-term neonates with bronchopulmonary dysplasia... full article
Pharma Focus Europe Editorial Team
August 13, 2025
Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing biologic therapies for respiratory, inflammatory, and infectious diseases, has received approval from the European Medicines Agency’s (EMA) Paediatric Committee (PDCO) for its Paediatric Investigation Plan (PIP) for zelpultide alfa... full article
MedPath Editorial Team
August 12, 2025
Airway Therapeutics announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for zelpultide alfa... full article
Progress, Potential, and Possibilities Podcast: Dr. Marc Salzberg, MD – CEO, Airway Therapeutics – Novel Biologics For Severe Respiratory Diseases
July 16, 2025
Dr. Marc Salzberg, MD is President, Chief Executive Officer & Chief Medical Officer of Airway Therapeutics, a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.... full article